Driehaus Capital Management LLC Purchases 493,194 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Driehaus Capital Management LLC increased its stake in Cellebrite DI Ltd. by 90.9%, acquiring 493,194 shares, bringing its total ownership to 1,036,022 shares valued at approximately $20.13 million.
• Analyst ratings for Cellebrite DI have varied, with JPMorgan Chase lowering its price target from $29.00 to $25.00, while Wall Street Zen upgraded it from "hold" to "buy", indicating mixed market sentiment.
• Cellebrite DI reported $0.12 earnings per share for the last quarter, exceeding expectations, with revenue increasing by 18.4% year-over-year to $113.28 million.

Driehaus Capital Management LLC raised its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 90.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,036,022 shares of the company's stock after purchasing an additional 493,194 shares during the period. Driehaus Capital Management LLC owned approximately 0.43% of Cellebrite DI worth $20,130,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Voss Capital LP boosted its stake in Cellebrite DI by 18.6% during the 1st quarter. Voss Capital LP now owns 3,843,602 shares of the company's stock valued at $74,681,000 after purchasing an additional 603,602 shares during the last quarter. Invesco Ltd. boosted its stake in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after purchasing an additional 1,811,757 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Cellebrite DI during the 1st quarter valued at $60,939,000. Two Sigma Advisers LP boosted its stake in Cellebrite DI by 35.0% during the 4th quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company's stock valued at $39,899,000 after purchasing an additional 470,000 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its stake in Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after purchasing an additional 1,340,000 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

Shares of CLBT stock traded down $0.14 during trading hours on Thursday, hitting $16.37. The stock had a trading volume of 4,336,036 shares, compared to its average volume of 2,422,649. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30. The stock's 50-day moving average price is $15.01 and its two-hundred day moving average price is $17.06. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of -21.54, a PEG ratio of 3.00 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. During the same period in the previous year, the firm posted $0.10 earnings per share. The business's revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Needham & Company LLC cut their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Finally, Lake Street Capital dropped their price target on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.